Overview
Dr. Palmer is physician investigator, clinician, and academic leader. He is a Donald F. Fortin, MD Distinguished Professor of Medicine at Duke University, Vice Chair for Research in the Department of Medicine, Director of Medicine Plus Therapeutic Area at the Duke Clinical Research Institute, and Director of Clinical Research in the Duke Transplant Center. He is an expert in the care of patients with advanced lung diseases and lung transplantation.
Dr. Palmer’s successful research career …
Current Appointments & Affiliations
Donald F. Fortin, M.D. Distinguished Professor of Medicine
·
2022 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Professor of Medicine
·
2015 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Vice-Chair for Research in the Department of Medicine
·
2013 - Present
Medicine, Pulmonary, Allergy, and Critical Care Medicine,
Medicine
Professor in Immunology
·
2016 - Present
Integrative Immunobiology,
Basic Science Departments
Professor in Population Health Sciences
·
2020 - Present
Population Health Sciences,
Basic Science Departments
Member in the Duke Clinical Research Institute
·
2003 - Present
Duke Clinical Research Institute,
Institutes and Centers
Core Faculty in Innovation & Entrepreneurship
·
2018 - Present
Duke Innovation & Entrepreneurship,
University Initiatives & Academic Support Units
In the News
View All News
Recent Publications
Identification and validation of a threshold for early posttransplant bronchoalveolar fluid hyaluronan that distinguishes lung recipients at risk for chronic lung allograft dysfunction.
Journal Article J Heart Lung Transplant · March 2025 BACKGROUND: Few tools exist for the early identification of patients at risk for chronic lung allograft dysfunction (CLAD). We previously showed hyaluronan (HA), a matrix molecule that regulates lung inflammation and fibrosis, accumulates in bronchoalveola ... Full text Link to item CiteExtent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.
Journal Article Respir Res · February 28, 2025 BACKGROUND: The prognostic value of patterns and quantitative measures of lung fibrosis on high-resolution computed tomography (HRCT) in patients identified as having progressive pulmonary fibrosis (PPF) has not been established. We investigated whether HR ... Full text Link to item CiteChanges in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.
Journal Article Chest · February 26, 2025 BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with lung function decline and high mortality. RESEARCH QUESTION: What are the associations between thresholds of lung function decline and the ... Full text Link to item CiteRecent Grants
Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMECo-Principal Investigator · Awarded by National Institutes of Health · 2018 - 2029Advanced Immunobiology Traning Program for Surgeons
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2019 - 2029Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMECo-Principal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028View All Grants
Education, Training & Certifications
Duke University ·
2000
M.H.S.
Duke University ·
1993
M.D.